Literature DB >> 7796104

Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21.

G W Arendash1, G J Sengstock, P R Sanberg, W R Kem.   

Abstract

The ability of two synthetic nicotine receptor ligands, TGS-21 and DMAB, to chronically enhance the cognitive function of aged rats was evaluated in three diverse tasks and compared to the cognition-enhancing effects of nicotine administration. 15 min prior to daily behavioral testing, aged 22-24 month old rats received an i.p. injection of nicotine (.02 mg/kg), GTS-21 (1 mg/kg), DMAB (2mg/kg), or saline vehicle and were tested in either one-way active avoidance pole jumping, Lashley III maze, or a 17-arm radial maze. GTS-21 pretreatment was as effective as nicotine for enhancing the acquisition of aged rats in both one-way active avoidance and Lashley III maze training. In 17-arm radial maze testing, GTS-21 improved both general learning and reference (long-term) memory to the same extent as nicotine. Although DMAB pretreatment enhanced reference memory in 17-arm radial maze testing to the same as nicotine, it did not affect general learning in this complex task and did not exert any cognition-enhancing effects in Lashley III maze training. These results indicate that GTS-21 has cognition-enhancing abilities in aged rats that are comparable to those of nicotine in a variety of behavioral tasks. Since GTS-21 acts preferentially on brain nicotinic receptors and is less toxic than nicotine, thses results further indicate that GTS-21 may have substantive therapeutic value in the treatment of age-associated memory impairment (AAMI) and/or Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796104     DOI: 10.1016/0006-8993(94)01449-r

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  49 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Axonal α7 nicotinic ACh receptors modulate presynaptic NMDA receptor expression and structural plasticity of glutamatergic presynaptic boutons.

Authors:  Hong Lin; Stefano Vicini; Fu-Chun Hsu; Shachee Doshi; Hajime Takano; Douglas A Coulter; David R Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-03       Impact factor: 11.205

3.  An autoradiographic analysis of rat brain nicotinic receptor plasticity following dietary choline modification.

Authors:  M V Guseva; D M Hopkins; J R Pauly
Journal:  Pharmacol Biochem Behav       Date:  2006-06-06       Impact factor: 3.533

4.  The involvement of central cholinergic system in the pressor effect of intracerebroventricularly injected U-46619, a thromboxane A2 analog, in conscious normotensive rats.

Authors:  Murat Yalcin; Sinan Cavun; M Sertac Yilmaz; Vahide Savci
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-26       Impact factor: 3.000

Review 5.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

6.  Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.

Authors:  Sung Won Kim; Yu-Shin Ding; David Alexoff; Vinal Patel; Jean Logan; Kuo-Shyan Lin; Colleen Shea; Lisa Muench; Youwen Xu; Pauline Carter; Payton King; Jasmine R Constanzo; James A Ciaccio; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2007-07       Impact factor: 2.408

7.  Boosting Endogenous Resistance of Brain to Ischemia.

Authors:  Fen Sun; Stephen R Johnson; Kunlin Jin; Victor V Uteshev
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

10.  Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.

Authors:  Frank G Boess; Jean de Vry; Christina Erb; Timo Flessner; Martin Hendrix; Joachim Luithle; Christoph Methfessel; Katrin Schnizler; F Josef van der Staay; Marja van Kampen; Welf-Burkhard Wiese; Gerhard König
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.